Protocol Ledger

NCT04628481 · Phase II · TERMINATED

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Interventional Phase II clinical trial protocol NCT04628481 sponsored by Dompé Farmaceutici S.p.A in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-12 Enrollment: 289 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04628481
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)289 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04628481
Protocol FieldVerified Registry Value
NCT IdentifierNCT04628481
Consolidated Lead SponsorDompé Farmaceutici S.p.A
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment289 participants (ACTUAL)
Registered Start Date2021-01-12
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI